A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2018
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 07 Dec 2018 Planned primary completion date changed to 30 Aug 2019.
- 05 Sep 2018 Planned End Date changed from 1 Sep 2020 to 1 Aug 2020.
- 05 Sep 2018 Status changed from recruiting to active, no longer recruiting.